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Abstract 
Evidence has pointed to brain tumor stem cells (BTSC) as culprits behind human high-grade 
glioma (hHGG) resistance to standard therapy. Pre-clinical rodent models are the mainstay 
for testing of new therapeutic strategies. The typical model involves the intracranial injection 
of  human  glioma  cells  into  immunocompromised  hosts,  hindering  the  evaluation  of  tu-
mor-host responses and resulting in non-infiltrative tumors. The CT-2A model is an im-
munocompetent mouse model with potential to overcome these disadvantages. In this study, 
we confirmed the highly infiltrative nature of intracranial CT-2A tumors and optimized re-
producible injection parameters. We then generated neurospheres and established, for the 
first time, the stemness of this model. CT-2A expression of the BTSC marker, CD133, in-
creased from 2% in monolayer cells to 31% in fully-formed neurospheres. Investigation of 
three stem cell markers (Oct4, Nanog and Nestin) revealed a distinct stemness signature with 
monolayer cells expressing Oct4 and Nestin (no Nanog), and neurospheres expressing all 
three. Additionally, CT-2A cells were more proliferative and invasive than U87 cells, while 
CT-2A neurospheres were significantly more proliferative and invasive than either monolayer 
cells in vitro. Taken together, our results show that this model is a valuable tool for pre-clinical 
testing of novel therapeutics against hHGG and also affords the opportunity for investigation 
of BTSC in an immunocompetent setting. 
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Introduction 
Human high-grade gliomas (hHGG) continue to 
carry  a  grim  prognosis  for  patients.  Glioblastoma 
(GBM), the most malignant and, at the same time the 
most  common,  type  of  hHGG,  is  a  highly  invasive 
tumor  with  high  recurrence  rates  despite  treatment 
(1). Patients with GBM have a median survival of 14.6 
months and an overall survival of only 10% at 5 years 
after gold-standard treatment with surgery, ionizing 
radiation, and temozolomide (2). Recent evidence has 
suggested that brain tumor stem cells (BTSC) may be 
the  culprits  behind  hHGG  resistance  to  standard 
treatment and high patient mortality (3). 
Consistent with the general definition of cancer 
stem cells (CSC), BTSC demonstrate the capacity for 
self-renewal, multi-potency and tumorigenesis (4-8). 
BTSC  have  been  associated  with  expression  of  the 
surface  marker  Cluster  of  Differentiation  (CD)133 
(7,8). The ability of CD133+ BTSC to generate tumors 
has been well documented in pre-clinical models (7,8). 
Clinical studies have shown that CD133 expression in 
Ivyspring  
International Publisher    Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
167 
histological samples correlates with patient survival 
and clinical course (9-11) though some contend that it 
is  not  a  prognostically  significant  factor  (12).  Other 
stem cell (SC) markers, in addition to CD133, may also 
be clinically relevant in GBM. Octomer4 (Oct4) and 
Nanog are transcription factors traditionally known 
for maintaining embryonic stem cells in a pluripotent 
state, and have recently been associated with poorly 
differentiated GBM (13). Expression of Nestin, an in-
termediate  filament  protein  expressed  during  em-
bryogenesis  in  multi-lineage  progenitor  cells,  corre-
lates with tumor aggressiveness and patient survival 
(14,15).  Combined  detection  of  markers,  such  as 
CD133 and Nestin, may improve prognostic accuracy 
(15). Controversy exists as to the relative specificity of 
these markers, and a marker-independent method for 
BTSC has been proposed (16). However, there is gen-
eral agreement that the more highly malignant hHGG 
exhibit a higher degree of stemness. 
Pre-clinical  testing  of  novel  therapies  is  often 
performed  on  models  that  are  generated  from  the 
intracranial or subcutaneous injection of cells, either 
from established hHGG lines or from excised hHGG, 
into immunocompromised mice (17). Concerns on the 
use of these model systems are the relatively low his-
topathologic similarity to clinical tumors (17) and the 
inability  to  study  tumor-specific  immune  responses 
(18).  Immunocompetent  models,  as  a  group,  over-
come the concern of tumor-specific immune respons-
es, although in general, caution must be exercised in 
the translation of results from the pre-clinical to the 
clinical  setting.  While  other  animals  may  be  used, 
mice are the mainstay of research based on a number 
of practical factors, such as cost, ease of handling, and 
the availability of advanced mouse-specific transgenic 
technologies  (19,20).  Therefore,  immunocompetent 
mouse models are ideal in that they combine the ben-
efits of providing an immunologically relevant envi-
ronment with the advantages of working with mice 
(21-23).  The  first  immunocompetent  mouse  model 
described in the literature was Gl261, developed from 
the intracranial implantation of 3-methylcholanthrene 
pellets  into  C57/BL6  mice  (24).  Although  used  fre-
quently  for  investigations,  concerns  subsequently 
arose secondary to immunogenicity (25). 
The CT-2A model derives from a malignant as-
trocytoma  originally  formed  after  the  intracerebral 
implantation  of  20-methylcholanthrene  pellets  into 
C57/BL6  mice  (26).  The  tumor  was  maintained 
through  serial  intracranial  transplants  (27)  and  the 
CT-2A cell line was subseqently established. CT-2A 
tumors  are  p53  wild-type  and  recapitulate  several 
features of hHGG, including high mitotic index and 
cell  density,  nuclear  polymorphism,  hemorrhage, 
pseudopalisading necrosis, and microvascular prolif-
eration (21). CT-2A tumors are PTEN deficient (28), a 
characteristic present in up to 40% of hHGG (29) and 
70% of established hHGG cell lines (30).  
In the current study, we present the first charac-
terization  of  the  CT-2A  model’s  stemness.  We  first 
document baseline tumor volumes achievable in the 
CT-2A intracranial model with standardized cellular 
stereotactic injection parameters, and then provide an 
analysis  of  several  stem  cells  markers,  including 
CD133, Oct4, Nanog and Nestin. We also demonstrate 
the functional significance of these characeristics via 
examination  of  the  proliferative  and  invasiveness 
properties of the CT-2A cells in vitro. 
Materials and Methods 
Cells and culture conditions.  
The CT-2A cell line was generously donated by 
Dr.  Thomas  Seyfried  (Boston  College,  Boston,  MA). 
CT-2A  cells  were  cultured  in  Dulbecco’s  Modified 
Eagle Medium (DMEM) with high glucose (Hyclone 
Laboratories,  Logan,  UT  ),  supplemented  with  10% 
fetal  bovine  serum  and  1%  penicillin-streptomycin 
(Mediatech, Inc, Manassas, VA). Cells grew as an ad-
herent  monolayer  and  were  maintained  long-term 
according to standard sterile cell culture techniques. 
To  generate  neurospheres,  CT-2A  monolayer  cells 
were enzymatically dissociated and plated in 25 cm2 
culture dishes at a cell concentration of 1x105 cells/ml 
in DMEM/F-12 medium (Hyclone Laboratories, Lo-
gan,  UT)  containing  epidermal  growth  factor  at  20 
ng/ml  (R&D  Systems  Inc,  Minneapolis,  MN),  basic 
fibroblast growth factor at 20 ng/ml (R&D Systems, 
Inc,  Minneapolis,  MN)  and  B27  supplement  50x 
(Invitrogen, Carlsbad, CA ). Cells were incubated at 
37oC  in  humidified  air  with  5%  CO2.  Neurospheres 
were collected at both 7 and 14 days for analysis. 
Intracranial brain tumor model.  
Adult male C57/BL6 mice (Jackson Laboratory, 
Bar Harbor, ME) were housed in our fully accredited 
animal facility that conforms to NIH guidelines. Ex-
periments  were  carried  out  in  accordance  with  our 
Institutional Animal Care and Use Committee. Intra-
cranial  stereotactic  tumor  cell  injections  were  per-
formed according to previous methods (31). Briefly, 
after  a  midline  scalp  incision  and  identification  of 
bregma, a burr hole was made posterior to bregma 
and to the right of midline. CT-2A cells in 5 l of PBS 
were loaded into the Hamilton syringe attached to a 
power injector (Stoelting Co, Oak Dale, IL). Stereotac-
tic  injections  were  performed  over  5  minutes  to  a 
depth of 3 mm. In one group, 5x105 cells were injected  Journal of Cancer 2012, 3 
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per mouse (n=8) and mice sacrificed at 4 weeks. In 
another  group,  1x106  cells  were  injected  per  mouse 
(n=6)  and  mice  sacrificed  at  3  weeks.  Brains  were 
fixed  in  4%  paraformaldehyde  at  4oC  for  48  hours. 
After slicing 10-m thick serial coronal sections, tissue 
was stained with haematoxylin and eosin and evalu-
ated by light microscopy with an Olympus BX51 mi-
croscope (Olympus America Inc, Center Valley, PA). 
Images were captured with a Nikon Digital Site-DSL1 
camera  (Nikon  Incorporated,  Melville,  NY).  Tumor 
area was calculated by Image J (NIH, Bethesda, MD) 
and  tumor  volume  was  determined  by  multiplying 
the tumor area by intervening thickness, calculated by 
multiplying section thickness by the number of sec-
tions. 
Immunofluorescence analysis.  
Tissue sections were air dried, treated with an-
tigen retrieval at 100oC for 5 minutes, blocked for 1 
hour with 10% goat serum and incubated overnight 
with  primary  anti-CD133  antibody  (1:100,  Abcam, 
Cambridge,  MA)  or  its  isotype  control  rabbit  IgG 
(1:100 Sigma, St. Louis, MO). Sections were then in-
cubated  for  1  hour  with  secondary  anti-rabbit  anti-
body conjugated to Cy3 (1:100, Invitrogen, Carlsbad, 
CA)  and  mounted  using  4’6-diamidino-2- 
phenylindole  (DAPI)-containing  medium  (Vector 
Labs, Burlingame, CA). Cells and neurospheres were 
seeded  onto  poly-D-lysin/laminincoated  slides  (BD 
Biosciences, Bedford, MA) overnight at 37oC and fixed 
with 4% paraformaldehyde. For intracellular marker 
detection,  permeabilization  was  performed  using 
0.1% Triton X. Cells were blocked with 10% serum for 
1 hour and incubated overnight at 4oC with the fol-
lowing primary antibodies and concentrations: CD133 
1:500  (Abcam,  Cambridge,  MA),  Oct4  (1:100  Bio-
vision,  Mountain  View,  CA),  Nanog  (1:200,  R&D 
Systems  Inc,  Minneapolis,  MN)  and  Nestin  (1:200 
Millipore, Billerica, MA). Cells were incubated for 1 
hour  with  the  secondary  antibodies  (Invitrogen, 
Carlsbad, CA) at the same concentration as follows: 
anti-rabbit-Cy3 (for CD133), anti-rabbit-Alexa488 (for 
Oct4),  anti-goat-FITC  (for  Nanog),  and  an-
ti-mouse-FITC (for Nestin). Cell nuclei were counter-
stained  with  DAPI  (Sigma-Aldrich,  St.  Louis,  MO). 
Slides were observed and imaged under fluorescence 
microscopy with a Leica DMI 4000B microscope and 
DFC340FX  camera  (Leica  Microsystems,  Bannock-
burn, IL).  
Flow cytometric analysis.  
CT-2A monolayer cells, as well as 1 week and 2 
week  neurospheres  were  washed  in  cold  PBS.  An-
ti-CD133 antibody (1:300, Abcam, Cambridge, MA ) 
was added for 30 minutes at 4oC. Unstained cells and 
cells stained  with  Rabbit IgG (Invitrogen,  Carlsbad, 
CA) were used as controls. Samples were then incu-
bated  with  secondary  anti-rabbit-Alexa488  antibody 
(1:300 Invitrogen, Carlsbad, CA) for 30 minutes at 4oC. 
After washing with cold PBS, samples were immedi-
ately  analyzed  using  FACScan  cytometer  (Beckton 
Dickinson,  San  Jose,  CA)  with  CellQuest  software 
(Beckton Dickinson, San Jose, CA). 
Reverse Transcriptase-Polymerase Chain Re-
action (RT-PCR).  
Cells were lysed with RNeasy lysis buffer and 
-mercaptoethanol and total RNA was extracted with 
RNeasy  kit  (Qiagen,  Valencia,  CA)  following  the 
manufacturer’s  instructions.  All  RNA  preparations 
were quantified with spectrophotometry prior to RT 
and 1 g of total RNA was used to generate comple-
mentary DNA (cDNA) using the First-Strand Super-
script II RT kit (Invitrogen, Carlsbad, CA). The cDNA 
was amplified in a total reaction volume of 50 l. All 
PCR  amplifications  were  for  30  cycles.  Amplified 
materials  were  examined  on  1.8%  agarose  gels  and 
photographed using an Eagle Eye II imager (Strata-
gene.,  La  Jolla,  CA).  The  following  primers  (Allele 
Biotech,  San  Diego,  CA)  were  used:  Oct4  (123bp, 
forward 5’->3’:AACCTGGAGTTTGTGCCAGGGTTT, 
reverse 5’->3’ TGAACTTCACCTTCCCTCCAACCA), 
Nanog  (361  bp,  forward  5’->3’:  AGGGTCTGCT 
ACTGAGATGCTCTG,  reverse  5’->3’CAACCACT 
GGTTTTTCTGCCACCG)  Nestin  (445  bp,  forward 
5’->3’: TTCCCCCTTGCCTAATACCCT, reverse 5’->3’ 
TACCTCTGTGGCTGCTTCTTT),  and  GAPDH  (470 
bp, forward 5’->3’: TGAAGGTCGGTGTGAACGGA, 
reverse 5’->3’ CAGGGGGGCTAAGCAGTTGGT).  
Proliferation assay in vitro.  
Cells and neurospheres (1x105 cells) were seeded 
on  poly-d-lysine  coated  glass  coverslips  overnight. 
After  pulsing  with  Bromodeoxyuridine  (BrdU)  at  a 
final  concentration  of  10  M  for  2  hours,  cells  and 
neurospheres were fixed with 4% PFA, permeabilized 
using 0.1% Triton in PBS and denatured with 2N HCl. 
They were washed with 0.1M Na2B4O7 (pH 8.5) and 
incubated  overnight  at  4oC  with  primary  anti-BrdU 
monoclonal  antibody  (1:500,  Sigma,  St.  Louis,  MO). 
Cells  and  neurospheres  were  then  incubated  for  1 
hour  at  room  temperature  with  secondary  goat  an-
ti-mouse Alex 488 (1:500, Invitrogen, Carlsbad, CA) 
and  counterstained  with  DAPI.  Slides  were  imaged 
using a Leica DMI 4000B microscope and DFC340FX 
camera  (Leica  Microsystems,  Bannockburn,  IL). 
BrdU/DAPI  double  positive  cells  in  four  randomly  Journal of Cancer 2012, 3 
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chosen fields were counted using ImageJ (NIH, Be-
thesda, MD).  
Invasion assay in vitro.  
Matrigel-coated 24-well invasion chambers were 
used  according  to  the  manufacturer’s  specifications 
(BD  Biosciences,  Bedford,  MA).  Briefly,  U87  and 
CT-2A  cells,  as  well  as  CT-2A  neurospheres  were 
plated in the upper transwell chambers of coated in-
serts at a concentration of 1x104 cells/500 l in serum- 
and growth factor-free media. The bottom wells of the 
chambers were filled with 500 l of medium contain-
ing 7% FBS chemoattractant. After 24 hours at 37oC, 
inserts were fixed in methanol and stained using the 
Hema 3 stain set (Fisher  Diagnostiscs, Middletown, 
VA) according to manufacturer’s instructions. Inserts 
were visualized with a Zeiss Axiovert 25 microscope 
(Carl Zeiss Inc, New York, NY) and twenty randomly 
chosen images acquired with Qicam (Qimaging, Sur-
rey, BC, Canada). Cells were counted using Image J 
software (NIH, Bethesda, MD).  
Statistical Analysis.  
When  applicable,  results  are  displayed  as  the 
mean  ±  standard  deviation  of  3  experiments  per-
formed in duplicate. Statistical significance was cal-
culated using the Student’s t-test with p ≤ 0.05. 
 
Results 
Evaluation of experimental tumors.  
Although  the  histologic  characteristics  of  the 
CT-2A model are well reported, tumor volumes are 
not.  We  first  established  baseline  tumor  volumes 
achievable with standardized cellular stereotactic in-
jection parameters that could be reliably reproduced. 
A  tumorigenesis  rate  of  100%  and  tumors  with  an 
acceptable  standard  deviation  were  obtained  by  in-
jecting 5x105 cells and evaluating tumor volume at 3 
weeks  (Table  1).  Histologic  analysis  of  the  tumors 
confirmed their hemorrhagic and infiltrative pattern 
into  both  the  adjacent  brain  parenchyma  and  more 
distant sites, resulting in satellite lesions (Figure 1A), 
thereby  recapitulating  key  features  of  hHGG.  The 
infiltrative nature of the CT-2A tumors, together with 
evidence supporting CD133 as BTSC marker (3) and 
implicating BTSC in infiltration (32), led us to explore 
CD133 expression in CT-2A intracranial tumors. To 
maximize detection based on the known association 
with hypoxia (33), we chose a specimen with a large 
tumor bulk and areas of necrosis (Figure 1B). Immu-
nofluorescent staining demonstrated areas of CD133 
expression  scattered  within  necrotic  regions  of  the 
tumor  (Figure  1C),  consistent  with  the  presence  of 
BTSC. 
Table 1. Injection parameters and results for the CT-2A 
intracranial mouse model. 
Intracranial  
CT-2A injection  
5x105 cells/ 5 ml PBS 
(n=8) 
1x106 cells / 5 ml PBS 
(n=6) 
Tumor Volume   229 ± 358 mm3  137 ± 64 mm3 
Volume Range   4 to 998  75 to 256 
Tumorigenesis  87.5 %  100% 
Time  4 weeks  3 weeks 
 
 
 
Figure 1. Histological features of the CT-2A orthotopic 
immunocompetent hHGG model. A and B) Light micros-
copy  photomicrographs  of  coronal  brain  sections  with  CT2A 
tumors. Tumors were hemorrhagic and demonstrated infiltration 
into brain parenchyma, including satellite lesions (A). Tumors with 
large bulk had necrotic areas throughout (arrows in B). Magnifi-
cation, 4x. Scale bar, 500 M. C) Immunofluorescence photomi-
crograph showing CD133 expression (Cy3 stain) in a necrotic area 
within the tumor. Magnification, 20x. Scale bar, 200 M  Journal of Cancer 2012, 3 
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Cell and neurosphere expression of CD133.  
To characterize the stemness of this model, we 
first generated CT-2A neurospheres and then charac-
terized  their  expression  of  CD133,  a  classical  BTSC 
marker (3). Although neurospheres began forming as 
early  as  4  days  when  cultured  in  serum-free  and 
growth-factor enriched medium, 2 weeks were nec-
essary  for  the  majority  of  neurospheres  to  be  fully 
formed  and  free  floating  (Figure  2A).  Immunofluo-
rescence  staining  demonstrated  increasing  CD133 
staining as cells progressed from monolayer to 1 and 2 
week  neurospheres  (Figure  2B).  Quantification  of 
CD133 staining via flow cytometry revealed increased 
CD133 expression, from 2% in monolayer cells to 7.3% 
in 1 week neurospheres and to 31.1% in the 2 week 
neurospheres (Figure 2C). Unstained control samples 
were  set  to  ≤  1%  and  isotype  control  staining  re-
mained ≤ 2% across all samples. 
Cell and neurosphere expression of other 
stem-cell markers: Oct4, Nanog, Nestin.  
The  presence  of  CD133  staining  in  CT-2A  tu-
mors,  as  well  as  cells  and  neurospheres,  motivated 
further investigation into the model’s stemness. We 
chose Oct4, Nanog and Nestin as markers to complete 
our stemness signature not only based on the clinical 
documentation  of  these  markers  (13-15) but  also  on 
basic studies linking their expression to BTSC func-
tion  (34-36).  As  shown  via  immunofluorescence 
staining (Figure 3A), Oct4 and Nestin were both pre-
sent in both monolayer cells and neurospheres, while 
Nanog was only present in the neurospheres. These 
results were also confirmed by RT-PCR (Figure 3B).  
 
Figure 2. CT-2A cells and neurospheres express CD133. A) Phase contrast images showing the transition from CT-2A adherent 
monolayer cells into fully floating neurospheres over the course of 2 weeks. B) Immunofluorescence analysis demonstrating increasing 
CD133 staining as cells progressed from a monolayer to 2 week neurospheres (nsp). A and B: magnification, 10x; scale bar, 100 m. C) 
CD133 expression quantified by flow cytometry shows 2.0%, 7.0% and 31.1% in the monolayer, 1 week and 2 week neurospheres, 
respectively. Unstained control samples were ≤ 1% and isotype control staining was ≤ 2.0%.   Journal of Cancer 2012, 3 
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Figure 3. CT-2A cells and neurospheres also express the SC markers: Oct4, Nanog and Nestin. A) Immunofluorescence 
analysis of SC marker expression (Oct4, Nanog and Nestin) in monolayer (left panel), 1week neurospheres (middle panel) and 2week 
neurospheres (right panel). Oct 4 was present in monolayer cells, and both 1week and 2week neurospheres. Nanog absent in the 
monolayer, but present in both 1 and 2week monospheres. Nestin staining was present in monolayer, 1week and 2week neurospheres. 
A and B: magnification, 10x; scale bar, 100 m. B) RT-PCR corroborated the above findings in the robust expression of all 3 SC markers 
at 2 weeks. 
 
Proliferative and invasive properties in vitro. 
We then turned our attention to more functional 
aspects of our model and examined proliferation and 
invasion in vitro. These have long been recognized as 
significant obstacles in the development of effective 
therapeutic  strategies  for  hHGG.  In  addition  to  the 
well-established proliferative capacity of BTSC, recent 
evidence has also implicated BTSC in mechanisms of 
invasion (32). To place our results in a broader con-
text, we directly compared results to the more com-
monly used U87 cell line. CT-2A cells exhibited a sig-
nificantly higher proliferation rate compared to U87 
cells  (6.5±0.5%  vs  3.6±0.4%,  p<0.05),  while  CT-2A 
neurospheres had maximal (100%) proliferation rate 
(Figure 4A). Similar results were obtained via inva- Journal of Cancer 2012, 3 
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sion assay (Figure 4B). CT-2A cells were significantly 
more  invasive  than  U87  cells  (268±14  vs  156±25 
cells/hpf,  p<0.05),  while  CT-2A  neurospheres  were 
significantly more invasive than both U87 and CT-2A 
cells (p<0.05), with a trend towards increased inva-
sion with 2 week neurospheres compared to 1 week 
neurospheres.  
Discussion 
 Reproducible injection parameters and reasona-
ble  tumor  volume  standard  deviations  are  practical 
considerations that render models useful in the eval-
uation of experimental therapeutics. For this reason, 
we chose to begin our evaluation of the CT-2A model 
by establishing baseline tumor volumes using injec-
tions  of  cells  rather  than  minced  tissue  since  cells 
represent a system that is easier to standardize and 
less fraught with measurement error. In addition, we 
also confirmed the infiltrative nature of intracranial 
CT-2A  tumors.  Previous  reports  on  the  histological 
appearance  on  the  CT-2A  orthotopic  model  have 
some variation, with some authors reporting a tumor 
with subsets of cells infiltrating into surounding brain 
parenchyma (21) and others a more compact tumor 
with minimal local invasion (23). Discrepancy could 
be due, in part, to differences in injection parameters; 
we  and  others  (21)  injected  cell  suspensions,  while 
others implanted minced tissue (23). 
 
 
Figure 4. CT-2A neurospheres are highly proliferative and invasive in vitro. A) Immunofluorescence photomicrographs after 
BrDU incorporation (green) showing stronger incorporation consistent with increased proliferation in CT2A neurospheres compared to 
CT2A and U87 monolayer cells (Alexa488 green, DAPI blue). B) Phase contrast photomicrographs of an in vitro invasion assay showing 
that CT-2A neurospheres were more invasive than CT-2A and U87 monolayer cells (Hema3 stain). A: magnification, 10x; scale bar 100 
m. B: magnification, 40x; scale 400 m. C and D) Bar graphs quantifying the above results confirm a statistically significant increase in 
both proliferation (C) and invasion (D) in the CT-2A neurospheres compared to the CT-2A and U87 monolayer cells. Data reported as 
mean ± SD (#p<0.05 compared to U87, * p<0.05 compared to CT-2A, per Student’s t-Test).  Journal of Cancer 2012, 3 
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 Although there is controversy surrounding the 
specificity of CD133 as a BTSC marker (3), it nonthe-
less  represents  one  of  the  most  widely  used  BTSC 
markers and enables a direct comparison with other 
glioma cell lines. We quantified the CD133 expression 
in the CT-2A model for the first time and found posi-
tivity not only in the CT-2A intracranial tumors but 
also in both cells and neurospheres, which we gener-
ated for the first time. CT-2A monolayer cells had a 
CD133 expression of 2%, which is significantly higher 
than the 0.5% to 0.9% reported in the literature for the 
U87 cell line (37,38), one of the most comonly used 
immunocompromised mouse models.  
In  characterizing  the  stemness  of  the  CT-2A 
model, we have also documented the expression of 
Oct4,  Nanog  and  Nestin.  While  CT-2A  monolayer 
cells expressed Oct4 and Nestin (no Nanog), neuro-
spheres expressed all three markers (Oct4, Nanog and 
Nestin). The upregulation of Nanog in neurospheres 
has  been  described  in  context  of  U87  neurospheres 
(39) and is consistent with data describing a correla-
tion  between  increased  CD133  and  Nanog  (35).  It 
could therefore represent a physiologic change as a 
result  of  neurosphere  development.  Several  studies 
have linked Oct4, Nanog and Nestin to BTSC devel-
opment and function (35-37) with implications for the 
identification  of  novel  therapeutic  signaling  targets 
such as STAT3 (35), which has gained recent attention 
as a likely therapeutic target for BTSC (40). The rele-
vance  of  stemness  signature  characterization  has 
found recent support in a study using computational 
methods to identify clinically useful compounds that 
could  target  cancers  with  high  stemness  signatures 
(41).  Therefore,  knowledge  of  the  CT-2A  stemness 
signature may be used to provide insight into BTSC 
responses to novel therapies. 
Previous data has demonstrated that BTSC have 
elevated invasive potential to non-BTSC (33). There-
fore,  it  is  not  surprising  that  CT-2A  neurospheres 
have  significantly  higher  proliferative  and  invasive 
properties in vitro compared to the monolayer cells. 
The increase in proliferation and invasion of CT-2A 
neurospheres compared to monolayer cells coincided 
with  the  expression  of  all  three  SC  markers  (Oct4, 
Nanog and Nestin) in neurospheres compared to two 
SC  markers  (Oct4  and  Nestin)  in  monolayer  cells. 
These results also highlight the relevance of examin-
ing a stemness signature rather than focusing on one 
SC marker alone.  
Taken together, our results show that the CT-2A 
pre-clinical  mouse  model  not  only  recapitulates  the 
histological features of hHGG but is also amenable to 
pre-clinical  testing  of  novel  therapies  in  the  immu-
nocompetent  host.  CT-2A  cells  and  neurospheres 
have distinct stemness features and are highly prolif-
erative  and  invasive.  These  characteristics  offer  the 
potential for investigating BTSC in an immunocom-
petent environment that may be of value given their 
emerging role in the resistance of hHGG to standard 
therapies. 
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